Etrasimod - Inflammatory bowel disease

You are here : Home > Formulary Search > Etrasimod - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

ICB

NICE

Restrictions / Comments :

Important

NICE guidance applies to Ulcerative Colitis patients only

Documents :

Evidence Review

Etrasimod in UC NICE TA956 Briefing paper May 2024.pdf

Webpage

Etrasimod for treating ulcerative colitis NICE TA956

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Etrasimod

Indication :

Inflammatory bowel disease

Group Name :

Keywords :

IBD-C, ulcerative colitis, NICE, sphingosine-1-phosphate (S1P) receptor modulator, high cost immunomodulator,

Brand Names Include :

Velsipity

Important Information :

Ulcerative colitis only

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Inflammatory bowel disease

Supporting Documents :

Other Indications

Below are listed other indications that Etrasimod is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Inflammatory bowel disease.

Committee Recommendations (2)

02 Oct 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found in the IBD guidelines page.

03 May 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves etrasimod as a treatment option in line with the recommendations made in NICE TA956, for treating moderately to severely active ulcerative colitis in people aged 16 years and over.

Etrasimod for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.